The Paradox of Muscle Hypertrophy in Muscular Dystrophy
Joe N. Kornegay(Texas A&M University), Kathryn R. Wagner(Kennedy Krieger Institute), Martin K. Childers(University of Washington), Jennifer L. Dow(University of North Carolina at Chapel Hill), Daniel J. Bogan(University of North Carolina at Chapel Hill), Robert W. Grange(Virginia Tech), James F. Howard(University of North Carolina at Chapel Hill), Zheng Fan(China Pharmaceutical University), Martin Styner(University of North Carolina at Chapel Hill), Peter P. Nghiem(Texas A&M University), Scott J. Schatzberg(Georgia College & State University), Eric P. Hoffman(Binghamton University), Jiahui Wang(Hangzhou Normal University), Janet R. Bogan(University of North Carolina at Chapel Hill)
Physical Medicine and Rehabilitation Clinics of North America
January 10, 2012
Cited by 111
Related Papers
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
|The Lancet Neurology|2017|820
Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis
|Oncogenesis|2017|707
Expression Profiling in the Muscular Dystrophies
|The Journal of Cell Biology|2000|481
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
|Annals of Neurology|2008|466